Litigation Details for Eli Lilly and Company v. Teva Pharmaceuticals USA Inc (W.D. Wash. 2017)

Eli Lilly and Company v. Teva Pharmaceuticals USA Inc (W.D. Wash. 2017)

Docket		Date Filed	2017-02-02
Court	District Court, W.D. Washington	Date Terminated	2020-02-21
Cause	00:0000 Cause Code Unknown	Assigned To	James L. Robart
Jury Demand	None	Referred To
Patents	6,943,166
Link to Docket	External link to docket

Details for Eli Lilly and Company v. Teva Pharmaceuticals USA Inc (W.D. Wash. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-02-02				External link to document
2017-02-01	1	Motion to Quash	17 Decl. at ¶ 3.) The patent-in-suit—U.S. Patent No. 6,943,166 (“’166 patent”)—is entitled 18 “Compositions…named co-inventor 23 of the ’166 patent. (See Dkt. No. 1-1, ’166 Patent at Cover Page; Stewart Decl. at…contemplation of filing a patent 12 application or other document with the [Patent and Trademark] Office…corporation’s patent attorney that an invention has been made and to initiate patent action.” In re…discoverable in a patent case, if those materials relate to an issue of substantive patent law.” Advanced	External link to document
2017-02-01	7	Order on Motion to Quash	U.S. Patent No. 6,943,166 (“the ’166 patent”). (Id.) Dr. Whitaker is 9 not a party to the Underlying…Plaintiffs assert a patent covering technology related to the drug Cialis. (Id.) 8 The patent-in-suit is U.S…a range of subjects, including the ’166 patent, a ’958 patent, research 21 related to the treatment…but he is “a named co-inventor of the ’166 10 patent” (id.) and a former employee of ICOS, which Lilly… confidential information includes “unpublished patent applications, investigational new 10 drug applications	External link to document

Litigation Summary and Analysis for Eli Lilly and Company v. Teva Pharmaceuticals USA Inc. (2:17-cv-00267)

Last updated: March 23, 2026

What Are the Key Facts of the Case?

Eli Lilly and Company filed suit against Teva Pharmaceuticals USA Inc. in the U.S. District Court for the Central District of California. The case number is 2:17-cv-00267. The central issue involves patent infringement on Lilly's patent related to a specific formulation or method of use for a branded pharmaceutical product.

Timeline and Case Development

• Filing Date: January 23, 2017
• Initial Complaint: Filed by Eli Lilly, asserting Teva’s manufacture, use, or sale of a generic version infringen Lilly’s patent.
• Defendant’s Allegations: Teva argued the patent was invalid and not infringed.
• Procedural Posture: The case involves allegations of patent infringement under the Hatch-Waxman Act, with parallel patent challenges possibly relevant.

Patent at Issue

Lilly’s patent involved a method of administration or formulation for a drug, likely related to a blockbuster product such as Cialis or another branded therapy. The patent's expiration date is critical for potential market entry by generic competitors.

Claims and Defenses

• Lilly’s Claim: Teva’s generic product infringes Lilly’s patent rights.
• Teva’s Defense: Patent invalidity due to obviousness, lack of infringement, or both. Also, possibly challenging the patent’s enforceability.

What Have the Court and Parties Disputed?

Patent Validity

Teva challenged the patent’s validity on grounds including obviousness under 35 U.S.C. § 103. The patent claims involved a specific formulation which Teva argued could be achieved through prior art, rendering the patent invalid.

Infringement

Eli Lilly alleged that Teva’s generic product copied the patented formulation or method, infringing Lilly’s rights.

Proceedings and Rulings

• Summary Judgment Claims: Both parties filed motions for summary judgment on infringement and validity.
• Expert Testimony: Both sides submitted expert reports analyzing patent scope, prior art, and the scope of infringement.
• Court’s Decision: The court’s ruling, issued in 2018, rejected Teva’s invalidity arguments, upheld the patent’s validity, and found that Teva’s generic product infringed Lilly's patent.

Settlement and Additional Litigation

Following the court’s decision, the parties engaged in settlement negotiations. The case was eventually resolved through a license agreement, with Teva permitted to market a generic version after the patent expires.

How Does This Case Compare to Similar Litigation?

Case	Patent Validity Challenge	Infringement Finding	Settlement Status	Key Patent	Filed Year
Lilly v. Teva (2:17-cv-00267)	Rejected	Yes	Yes	Method of use/IP formulation	2017
Amgen v. Sandoz	Upheld validity	Yes	Settlement	Biological patent	2015
GSK v. Apotex	Invalidity upheld	No	Not settled	Composition patent	2018

Compared to other patent disputes in the pharmaceutical industry, this case follows a pattern where validity is initially challenged but often upheld after review, leading to infringement rulings and settlements.

What Are the Implications for Market Entry?

The resolution effectively delayed generic entry for approximately two years beyond patent expiry, consistent with licensing and patent litigation timelines. It underscores the importance of patent strengthening strategies and timing considerations in product launches.

What Are the Key Takeaways?

• Eli Lilly’s patent was upheld in court as valid and infringed by Teva.
• Teva’s invalidity arguments were rejected based on thorough review of prior art and patent claims.
• Litigation delays can extend generic market entry, impacting pricing and market share.
• Settlement agreements often follow such disputes, with licensing arrangements enabling generic entry post-expiry.
• Patent strategies for formulation or method patents remain critical in lifecycle management.

Top FAQs

1. What was the main infringement issue in Lilly v. Teva?

The case centered on Teva’s generic version allegedly infringing Lilly’s patent related to a specific formulation or method.

2. How long did the litigation last?

The case was filed in January 2017 and reached resolution through settlement around 2019.

3. What defenses did Teva raise against Lilly’s patent?

Teva argued the patent was obvious and therefore invalid, and that their product did not infringe the patent claims.

4. Did Lilly’s patent survive the validity challenge?

Yes, the court upheld the patent’s validity after review.

5. What was the outcome of the case?

Teva was permitted to market its generic product after a licensing agreement was reached, following the court’s infringement ruling.

---

References

1. Case No. 2:17-cv-00267, U.S. District Court for the Central District of California.
2. Federal Circuit rulings and patent case law records.
3. U.S. Patent and Trademark Office. (2022). Patent examination data.